Connect with us

Hi, what are you looking for?

Investing

Mirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer Patients

By Stephen Nakrosis


Mirati Therapeutics said on Friday the U.K.’s Medicines and Healthcare Products Regulatory Agency gave conditional marketing approval for Krazati to treat certain non-small cell lung cancer patients.

Krazati was given approval as a treatment for adult patients who have “advanced non-small cell lung cancer with KRAS(G12C) mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy,” the company said.

In December, Krazati received approval from the Food and Drug Administration as a treatment for certain adult patients with non-small cell lung cancer.

The biotechnology company said lung cancer is one of the most common cancers worldwide.


Write to Stephen Nakrosis at [email protected]


Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Uncategorized

Blogs Cons out of Gambling enterprises One to Capture Zimpler Dumps A lot more gambling enterprise percentage steps Making Withdraws during the Zimpler Casinos...

Uncategorized

Content Wager-Free Revolves from the MrQ to own Confirming Mobile King Kong Cash Claps Casino Zero wagering 100 percent free spins Instantaneous Earn online...

Uncategorized

Articles Will there be a free of charge Spins Offer having deposit offered by Mr Green? Gambling games What Number Hit Really within the...

Uncategorized

Content Twice Triple Chance Is actually the the newest Totally free position tournaments Superiores Casinos ripoff Recursos troll hunters máquina tragamonedas Real acerca de...